Canakinumab is a monoclonal antibody against interleukin-1β (IL-1β), mainly used to treat a variety of autoinflammatory diseases and gout attacks. Its mechanism of action is to reduce the inflammatory response by blocking the activity of IL-1β.
Instructions for Canakinumab
The instructions for Canakinumab cover important information such as its indications, dosage, adverse reactions and precautions, providing detailed guidance for clinical use.
Indications and Dosage
Canakinumab is suitable for a variety of periodic fever syndromes, including Cryopyrin protein-associated periodic syndrome (CAPS), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS) and familial Mediterranean fever (FMF). In addition, it is also used to treat Still's disease (adult Still's disease and systemic juvenile idiopathic arthritis) and gout attacks. Dosage is adjusted according to the patient's weight and disease type, usually subcutaneous injection once every 4 to 8 weeks.
Adverse reactions and precautions
Common adverse reactions include nasopharyngitis, injection site reactions, and upper respiratory tract infections. Increased risk of serious infection is one of the important precautions. Patients need to use it under the guidance of a doctor and avoid simultaneous vaccination with live vaccines. Special populations such as pregnant women, children, and elderly patients need to use the drug with caution.
The instructions for use of Canakinumab provide clinicians with comprehensive medication guidance to help patients use the drug safely and effectively.
Basic information about Canakinumab
Canakinumab is a sterile, preservative-free injection with the core ingredient Canakinumab, which targets IL-1β.
Dosage form and properties
Canakinumab is a clear to milky solution with a specification of 150 mg/mL. It needs to be stored in a dark place at 2-8°C and has a shelf life of 24 months. Avoid freezing or shaking during use to make sure that the solution is free of particles.
Manufacturer and price
Novartis AG of Switzerland is the original manufacturer of Canakinumab, which is packaged in 150 mg/mL. There are currently no generic drugs on the market.
The basic information of canakinumab provides an important reference for its clinical application, and its uniqueness is reflected from dosage form to price.
Pharmacokinetics of canakinumab
The pharmacokinetic properties of canakinumab are consistent with the typical characteristics of IgG antibodies, but are affected by body weight and disease type.
Absorption and distribution
Canakinumab is administered by subcutaneous injection, with a slow absorption rate and a peak blood concentration within a few days after administration. Its distribution volume is related to body weight, and those with lighter body weight may need to adjust the dose.
Metabolism and excretion
Canakinumab is mainly metabolized through the reticuloendothelial system and has a long half-life of about 26 days. Its clearance rate is affected by the inflammatory state, and patients with chronic inflammation may need more frequent dose adjustments.
The pharmacokinetic study of canakinumab provides a scientific basis for its individualized medication and helps optimize the treatment effect.
